ERYTECH to Host Fourth Quarter and Full Year 2018 Conference Call and Business Update
LYON, France, March 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2018 conference call and webcast on Tuesday, March 12, 2019, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 3291426#
USA/Canada: +1 (833) 818-6807
International Dial-In Number: +1 (409) 350-3501
France: +33 1 76 74 89 88
United-Kingdom: +44 2031070289
The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/bdbuhozf
An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 3291426 #. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com.
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.
ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.
ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).
ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Mohawk Industries Reports Q1 Results25.4.2019 22:15:00 CEST | Pressemelding
CALHOUN, Ga., April 25, 2019 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced 2019 first quarter net earnings of $122 million and diluted earnings per share (EPS) of $1.67. Adjusted net earnings were $154 million, and EPS was $2.13, excluding restructuring, acquisition and other charges. Net sales for the first quarter of 2019 were $2.44 billion, up 1% in the quarter and 6% on a constant currency and days basis. For the first quarter of 2018, net sales were $2.41 billion, net earnings were $209 million and EPS was $2.78, adjusted net earnings were $225 million, and EPS was $3.01, excluding restructuring, acquisition and other charges. Commenting on Mohawk Industries’ first quarter performance, Jeffrey S. Lorberbaum, Chairman and CEO, stated, “In the first quarter, we delivered results in-line with the high end of our expectations despite economies weakening in most regions and a stronger U.S. dollar, reducing our translated results. While U.S. housing markets beg
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 201925.4.2019 22:05:00 CEST | Pressemelding
GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019. Conference call details are as follows: Date: May 2, 2019 Time: 4:30 p.m. U.S. Eastern Time (ET) Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International) Passcode: 5394082 Webcast: www.novavax.com, “Investors”/ “Events” Conference call and webcast replay: Dates: Starting at 7:30 p.m. ET, May 2, 2019 until 7:30 p.m. ET May 9, 2019 Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International) Passcode: 5394082 Webcast: www.novavax.com, “Investors”/ “Events”, until August 2, 2019 About Novavax Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its tw
Oxford Immunotec Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 201925.4.2019 22:05:00 CEST | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2019 financial results before the open of the market on Thursday, May 9, 2019. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 6687808, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on th
BGRS Acquired by Relo Group, Inc.25.4.2019 17:55:00 CEST | Pressemelding
CHICAGO and TOKYO, April 25, 2019 (GLOBE NEWSWIRE) -- Relo Group, Inc. (“Relo Group”) and BGRS (“BGRS” or the “Company”) announced today that they have entered into a definitive agreement under which an affiliate of Relo Group will acquire BGRS, a leading global talent mobility management firm from Brookfield Business Partners. Leading the global mobility industry with innovative outsourcing and fully integrated solutions, BGRS provides a full spectrum of talent mobility and advisory services to Global Fortune 500 companies. Supported by a team of over 1,300 globally, BGRS manages over 60,000 employee relocations annually with locations throughout Asia, the Americas and EMEA. BGRS Chief Executive Officer, Traci Morris, and the management team will remain in place and work with Relo Group to advance the Company into its next phase. “BGRS has developed into a world class talent mobility management firm by always putting the interests of our clients first, constantly innovating and search
Ascom adds ‘talk before walk’ wireless speech function to new release of Ascom teleCARE IP25.4.2019 14:00:00 CEST | Pressemelding
New feature helps reduce caregivers’ walking time; enables more streamlined workflows in elderly care facilities BAAR, Switzerland, April 25, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), a global solutions provider focused on healthcare ICT and mobile workflow solutions, has added wireless speech functionality to its latest version of the Ascom teleCARE IP emergency call system. The new feature promises to help reduce the time spent by staff walking to investigate calls from residents in continuing and elderly care facilities. Ascom teleCARE IP has always had hardwired speech functionality. But by making it wireless, residents can simply use their normal mobile phones to communicate directly with caregivers via Ascom teleCARE IP. Caregivers can communicate with residents while on the go, and can deal with residents’ calls before walking to investigate. The newly released (Ascom teleCARE IP 12) is available globally. The latest version also features several technical enhancements inclu
LGC CAPITAL announces conditional approval of an amended private placement financing of $10,400,000 with Arlington Capital LP25.4.2019 14:00:00 CEST | Pressemelding
MONTRÉAL, April 25, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC") is pleased to announce that it has obtained conditional approval from the TSX Venture Exchange for its previously announced financing with Arlington Capital (please refer to LGC’s press release dated January 24, 2019). Since that announcement, both parties have agreed to increase the financing to $10.4 million from the previously announced $8 million. Pursuant to the private placement, Arlington Capital will subscribe for a total of 104,000,000 common shares of LGC at a price of $0.10 per share. As a result of this private placement, Arlington Capital will, on closing, become LGC’s largest shareholder holding 19.97% of LGC’s issued and outstanding common shares. There are no warrants with this financing. Use of proceeds are to accelerate LGC’s group of companies’ business plan for the current calendar year. As previously announced, on closing of the private placement, LGC will pay a 3% finde